Abstract

Twenty one phenylacetylshikonin analogues were synthesized from various substituted phenyl acetic acids and their cytotoxicity values against A549, K562 and L1210 cell lines and antitumor action in mice bearing S-180 cells were measured. All of phenylacetylshikonin analogues expressed a potent cytotoxicity (ED50, 0.1–1.80 μg/ml) against L1210 and K562 cells. L 1210 cells were the most sensitive to shikonin analogues among these cells. Except 4-methoxyphenylacetylshikonin (0.098μg/ml) and α-acetoxyphenylacetylshikonin (0.10μg/ml), all other shikonin derivatives showed higher ED50 values than phenylacetylshikonin (0.13μg/ml) in L 1210. In K562 cell, α-substitution of phenylacetylshikonin (0.1 μg/ml), while other substitutions increased it slightly; 4-methoxyphenylacetylshikonin (0.033 μg/ml) showed a exceptionally good cytotoxicity against K562 cell. 4-Halogenation tended to decrease the cytotoxic effect on L1210 cells, while it enhanced the effect on K562; 4-bromophenylacetyl [ED50 (L1210)=1.76 μ/ml, ED50 (K 562)=0.32 μg/ml] and 4-chlorophenylacetyl shikonin [ED50 (L 1210)=1.64 μg/ml, ED50 (K562)=0.32 μg/ml]. In contrast, A549 cells were much less sensitive to these shikonin analogues which showed ED50 values of 1.5–13.5 μg/ml. Most of phenylacetylshikonin derivatives showed good antitumor activity in mice bearing S-180 cells. α-A-cetoxyphenylacetylshikonin and 4-dimethylaminophenylacetylshikonin showed highest T/C value (192–195%), implying that introduction of α-acetyl or of 4-dimethyl amino group gave a positive effect on the antitumor activity. Introduction of 4-dimethylamino group enhanced the antitumor activity as shown for 4-dimethylaminophenylacetylshikonin (T/C, 192%). It might be due to improvement of water solubility by dimethylamino group in the molecule.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.